Inventor · disambiguated record
Michael Wittekind
Also filed as: WITTEKIND MICHAEL
27 granted patents·14 pending applications·722 citations·filing 2000–2024
97Inventor score
Files withCONTRAFECT CORP18BRISTOL MYERS SQUIBB CO7A ALPHA BIO INC3AMGEN INC2AUROBAC THERAPEUTICS SAS2
Top patents by PatentIndex Score
41 records- 0198US7858739B2Inhibitors of type 2 vascular endothelial growth factor receptorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Dec 28, 2010·84 cites·79 claims
- 0297US8324362B2Nucleic acid encoding 10FN3 polypeptide inhibitors of Type 2 vascular endothelial growth factor receptorsCHEN YAN·Filed 2010·Granted Dec 4, 2012·58 cites·10 claims
- 0397US7847062B2Pharmacokinetic modulation and compositions for modified FN3 polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Dec 7, 2010·77 cites·15 claims
- 0496US9862758B2Inhibitors of type 2 vascular endothelial growth factor receptorsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 9, 2018·20 cites·22 claims
- 0596US8609613B2Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptidesCHEN YAN·Filed 2012·Granted Dec 17, 2013·36 cites·20 claims
- 0696US8592562B2Method for making antibody Fc-heterodimeric molecules using electrostatic steering effectsKANNAN GUNASEKARAN·Filed 2009·Granted Nov 26, 2013·339 cites·18 claims
- 0795US9328157B2Inhibitors of type 2 vascular endothelial growth factor receptorsBRISTOL MYERS SQUIBB CO·Filed 2013·Granted May 3, 2016·26 cites·7 claims
- 0894US11726097B2Methods for characterizing and engineering protein-protein interactionsA ALPHA BIO INC·Filed 2022·Granted Aug 15, 2023·3 cites·13 claims
- 0994US11474111B2Methods for characterizing and engineering protein-protein interactionsA ALPHA BIO INC·Filed 2021·Granted Oct 18, 2022·5 cites·11 claims
- 1094US10744189B2Lysin polypeptides active against Gram-negative bacteriaCONTRAFECT CORP·Filed 2016·Granted Aug 18, 2020·8 cites·14 claims
- 1192US11413334B2Lysin polypeptides active against Gram-negative bacteriaCONTRAFECT CORP·Filed 2020·Granted Aug 16, 2022·2 cites·13 claims
- 1286US8193322B2Methods for generating monovalent IgGYAN WEI·Filed 2006·Granted Jun 5, 2012·19 cites·40 claims
- 1385US9499594B2Biofilm prevention, disruption and treatment with bacteriophage lysinCONTRAFECT CORP·Filed 2013·Granted Nov 22, 2016·6 cites·20 claims
- 1485US2025064902A1Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited therebyAUROBAC THERAPEUTICS SAS·Filed 2024·Application pending·0 cites
- 1584US6333186B1Modified forms of Hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease: inhibitor complexesBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Dec 25, 2001·20 cites·26 claims
- 1683US10995131B2Libraries of modified fibronectin type III tenth domain-containing polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted May 4, 2021·1 cites·14 claims
- 1780US6800456B2Modified forms of hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease:inhibitor complexesBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Oct 5, 2004·11 cites·15 claims
- 1880US2023277617A1Biofilm prevention, disruption and treatment with bacteriophage lysinCONTRAFECT CORP·Filed 2022·Application pending·0 cites
- 1977US9718875B2Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacyCONTRAFECT CORP·Filed 2016·Granted Aug 1, 2017·2 cites·16 claims
- 2077US2023050560A1Lysin polypeptides active against gram-negative bacteriaCONTRAFECT CORP·Filed 2022·Application pending·0 cites
- 2176US12144845B2Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited therebyAUROBAC THERAPEUTICS SAS·Filed 2022·Granted Nov 19, 2024·0 cites·14 claims
- 2275US9889181B2Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2013·Granted Feb 13, 2018·2 cites·12 claims
- 2372US11524046B2Biofilm prevention, disruption and treatment with bacteriophage lysinCONTRAFECT CORP·Filed 2019·Granted Dec 13, 2022·0 cites·43 claims
- 2472US2022251543A1Methods for characterizing and engineering protein-protein interactionsA ALPHA BIO INC·Filed 2021·Application pending·0 cites
- 2570US8460647B2Pre-ligand assembly domain of the IL-17 receptorGAFFEN SARAH L·Filed 2008·Granted Jun 11, 2013·3 cites·8 claims
- 2669US2021128696A1Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2021·Application pending·0 cites
- 2768US11357833B2Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited therebyCONTRAFECT CORP·Filed 2016·Granted Jun 14, 2022·0 cites·17 claims
- 2868US2021008175A1Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2020·Application pending·0 cites
- 2966US12491245B2Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereofCONTRAFECT CORP·Filed 2021·Granted Dec 9, 2025·0 cites·23 claims
- 3066US10813983B2Bacteriophage lysin and antibiotic combinations against gram positive bacteriaCONTRAFECT CORP·Filed 2013·Granted Oct 27, 2020·0 cites·8 claims
- 3161US11246928B2Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereofCONTRAFECT CORP·Filed 2019·Granted Feb 15, 2022·0 cites·35 claims
- 3259US11827693B2Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacyCONTRAFECT CORP·Filed 2014·Granted Nov 28, 2023·0 cites·36 claims
- 3357US2018221456A1Bacteriophage lysin and antibiotic combinations against gram positive bacteriaSCHUCH RAYMOND·Filed 2017·Application pending·0 cites
- 3455US2017127683A1Biofilm prevention, disruption and treatment with bacteriophage lysinSCHUCH RAYMOND·Filed 2016·Application pending·0 cites
- 3550US2017334974A1Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacyCONTRAFECT CORP·Filed 2017·Application pending·0 cites
- 3650US2014024111A1Host cell for making antibody fc-heterodimeric molecules using electrostatic steering effectsAMGEN INC·Filed 2013·Application pending·0 cites
- 3747US2008220049A1Compositions and methods for intraocular delivery of fibronectin scaffold domain proteinsADNEXUS A BRISTOL MYERS SQUIBB·Filed 2007·Application pending·0 cites
- 3846US2021032294A1MODIFIED PlySs2 LYSINS AND USES THEREOFCONTRAFECT CORP·Filed 2019·Application pending·0 cites
- 3940US2013302886A1Pre-Ligand assembly domain of the IL-17 receptorGAFFEN SARAH L·Filed 2013·Application pending·0 cites
- 4039US2015284471A1Human LCAT Antigen Binding Proteins and Their Use in TherapyAMGEN INC·Filed 2012·Application pending·0 cites
- 4138US10639370B2Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereofCONTRAFECT CORP·Filed 2015·Granted May 5, 2020·0 cites·8 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →